The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Blood Pressure Reduction in Mild Hypertension: A Systematic Review and Meta-analysis
Abstract
BACKGROUND: Effects of blood pressure reduction in persons with grade 1 hypertension are unclear. PURPOSE: To investigate whether pharmacologic blood pressure reduction prevents cardiovascular events and deaths in persons with grade 1 hypertension. DATA SOURCES: Trials included in the BPLTTC (Blood Pressure Lowering Treatment Trialists' Collaboration) and trials identified from a previous review and electronic database searches. STUDY SELECTION: Patients without cardiovascular disease with blood pressures in the grade 1 hypertension range (140 to 159/90 to 99 mm Hg) who were randomly assigned to an active (antihypertensive drug or more intensive regimen) or control (placebo or less intensive regimen) blood pressure-lowering regimen. DATA EXTRACTION: Individual-patient data from BPLTTC trials and aggregate data from other trials were extracted. Risk of bias was assessed for all trials. DATA SYNTHESIS: Individual-patient data involved 10 comparisons from trials where most patients had diabetes, and aggregate data involved 3 comparisons from trials of patients without diabetes. The average blood pressure reduction was about 3.6/2.4 mm Hg. Over 5 years, odds ratios were 0.86 (95% CI, 0.74 to 1.01) for total cardiovascular events, 0.72 (CI, 0.55 to 0.94) for strokes, 0.91 (CI, 0.74 to 1.12) for coronary events, 0.80 (CI, 0.57 to 1.12) for heart failure, 0.75 (CI, 0.57 to 0.98) for cardiovascular deaths, and 0.78 (CI, 0.67 to 0.92) for total deaths. Results were similar in secondary analyses. Withdrawal from treatment due to adverse effects was more common in the active groups. LIMITATION: Blood pressure reductions and numbers of events were small. CONCLUSION: Blood pressure-lowering therapy is likely to prevent stroke and death in patients with uncomplicated grade 1 hypertension. PRIMARY FUNDING SOURCE: Swedish Heart-Lung Foundation, Swedish Research Council, Australian Research Council, and National Health and Medical Research Council of Australia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Self-citationJames, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14739-3 · Cited by 2,402
Self-citationDanaei, G., Finucane, M. M., Lin, J. K., Singh, G. M., Paciorek, C. J., Cowan, M. J., Farzadfar, F., Stevens, G. A., Lim, S. S., Riley, L. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62036-3 · Cited by 1,239
Estacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N., & Schrier, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803053381003 · Cited by 1,166
Preventing Microalbuminuria in Type 2 Diabetes
Ruggenenti, P., Fassi, A., Ilieva, A. P., Bruno, S., Iliev, I. P., Brusegan, V., Rubis, N., Gherardi, G., Arnoldi, F., Ganeva, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042167 · Cited by 1,020
Schrier, R. W., Estacio, R. O., Esler, A., & Mehler, P. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00213.x · Cited by 851
Franklin, S. S., Jacobs, M. J., Wong, N. D., L’Italien, G. J., & Lapuerta, P. (2001) · Hypertension · doi:10.1161/01.hyp.37.3.869 · Cited by 706
Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria
Asselbergs, F. W., Diercks, G. F. H., Hillege, H. L., van Boven, A. J., Janssen, W. M. T., Voors, A. A., de Zeeuw, D., de Jong, P. E., van Veldhuisen, D. J., & van Gilst, W. H. (2004) · Circulation · doi:10.1161/01.cir.0000146378.65439.7a · Cited by 523
Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system
(2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280bad9b4 · Cited by 414
Marre, M., Lievre, M., Chatellier, G., Mann, J. F. E., Passa, P., & Ménard, J. (2004) · BMJ · doi:10.1136/bmj.37970.629537.0d · Cited by 296
Meta‐analysis of continuous outcomes combining individual patient data and aggregate data
Riley, R. D., Lambert, P. C., Staessen, J. A., Wang, J., Gueyffier, F., Thijs, L., & Boutitie, F. (2008) · Statistics in Medicine · doi:10.1002/sim.3165 · Cited by 279
Teo, K. K., Burton, J. R., Buller, C. E., Plante, S., Catellier, D., Tymchak, W., Dzavik, V., Taylor, D., Yokoyama, S., & Montague, T. J. (2000) · Circulation · doi:10.1161/01.cir.102.15.1748 · Cited by 275
MacMahon, S., Sharpe, N., Gamble, G., Clague, A., Ni Mhurchu, C., Clark, T., Hart, H., Scott, J., & White, H. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00736-1 · Cited by 235
Pharmacotherapy for mild hypertension
Diao, D., Wright, J. M., Cundiff, D. K., & Gueyffier, F. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006742.pub2 · Cited by 194
Individualized Guidelines: The Potential for Increasing Quality and Reducing Costs
Eddy, D. M., Adler, J. S., Patterson, B., Lucas, D., Smith, K. A., & Morris, M. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00008 · Cited by 152
Gaziano, T. A., Steyn, K., Cohen, D. J., Weinstein, M. C., & Opie, L. H. (2005) · Circulation · doi:10.1161/circulationaha.105.535922 · Cited by 149
EVALUATION OF DRUG TREATMENT IN MILD HYPERTENSION: VA‐NHLBI FEASIBILITY TRIAL*
Neurath, H. M., Goldman, A. I., Lavin, M. A., Schnaper, H. W., Fitz, A. E., Frohlich, E. D., Steele, B. W., & Richman, H. G. (1978) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1978.tb25604.x · Cited by 91
Montgomery, A. A., Fahey, T. P., Ben‐Shlomo, Y., & Harding, J. G. (2003) · Journal of Hypertension · doi:10.1097/00004872-200309000-00026 · Cited by 82
Cobiac, L. J., Magnus, A., Barendregt, J. J., Carter, R., & Vos, T. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-398 · Cited by 76
Jackson, P. (2003) · Journal of Hypertension · doi:10.1097/00004872-200309000-00010 · Cited by 75
Kjeldsen, S. E., Stålhammar, J., Hasvold, P., Bodegård, J., Olsson, U., & Russell, D. (2009) · Journal of Human Hypertension · doi:10.1038/jhh.2009.77 · Cited by 62
Neal, B. C., & MacMahon, S. W. (1999) · Current Hypertension Reports · doi:10.1007/s11906-999-0045-2 · Cited by 48
Self-citationChalmers, J., Arima, H., Harrap, S., Touyz, R. M., & Park, J. B. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835f7eef · Cited by 43
Self-citation
Cited by
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Metadata
- Authors
- Sundström, J., Arima, H., Jackson, R., Turnbull, F., Rahimi, K., Chalmers, J., Woodward, M., Neal, B., & on behalf of the Blood Pressure Lowering Treatment Trialists' Collaboration*
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2015-02-03
- Volume
- 162
- Issue
- 3
- Pages
- 184-191
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2165927787
- Cited by
- 262
- References
- 36
- FWCI
- 16.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.